EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.

Roksana Riddle and Christopher H. Contag from Michigan State University discuss the concept of endosymbiosis, how it has ...

Professional diver Andrew Ryzebol tells PEOPLE exclusively of his risky underwater explorations 200 feet beneath uncharted ice with nothing but a mask and fins.

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for third-line sacituzumab govitecan.

We recently compiled a list of the 10 Best Debt Free Mid Cap Stocks to Buy Now. In this article, we are going to take a look ...

The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...

What Happened? Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the ...